News Vaccinex Releases Pre-clinical Data on Experimental Multiple Sclerosis Therapy Vaccinex Releases Pre-clinical Data on Experimental Multiple Sclerosis Therapy by Patricia Silva, PhD | April 2, 2015 Share this article: Share article via email Copy article link Vaccinex, Inc. recently announced positive resultsĀ for a multi center, randomized, double-blinded, placebo-controlled phase 1 clinical trial that evaluatedĀ single ascending-dose tolerability and safety inĀ an experimental treatment for Multiple Sclerosis (MS) adult patients. The researchers enrolled 50 MS patients in one of fiveĀ study groups (1, 3, 6, 10, and 20 mg/kg) to assess the tolerability and safety of the new compound VX15/2503 that was IV-administered in a single dose. VX15/2503 is a first in class, monoclonal antibody that Vaccinex discovered, characterized, and examined in Multiple Sclerosis and Huntington’s Disease preclinical models. Results from the studyĀ revealed the drug is well tolerated at dosesĀ of up to 20 mg per kg. The results also showed no major adverse effects during treatmentĀ withĀ no maximum tolerated dose (MTD) determined and noĀ dose-limiting toxicities (DLTs). [adrotate group=”4″] After aĀ preliminary analysis, researchers determined that the half-life of a single drug dose is between 21 and 23 days at the dose level of 20 mg/ per kg, and that saturation of the specific SEMA4D drug-target receptor persisted for about 155 days. The company is planning to publish these preliminary results in a peer-reviewed journal. Vaccinex willĀ begin a new phase 2 study during the first half of 2015, to test the efficacy of its VX15/2503 antibody in patients with Huntington’s Disease.Ā The company is actively working in discovering and developing human therapeutic monoclonal antibody solutions for cancer treatment. Vaccinex is also committed to advancing therapeutic solutions for neurodegenerative diseases, such as multiple sclerosis and Huntington’s Disease. The company’s proprietary ActivMAb Antibody Discovery Technology includes a mammalian cell-based antibody selection and is part of Vaccinex’s antibody pipeline. The system combines the benefits of a fast and precise selection throughĀ virus panning and cell sorting all in one single technology, with key selection of antibodies that are efficiently expressed and stable in mammalian cells. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.
April 24, 2024 News by Lindsey Shapiro, PhD Autoantibodies seen in blood years before MS diagnosis: Study
April 23, 2024 News by Mary Chapman Itās year 10 for MSAAās upcoming Improving Lives Benefit for MS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year